|
Basic patient characteristics and blood stream infections (BSI). |
|||
| Item |
Group 1 (heparin) |
Group 2 (TauroLock™) |
P value |
|
|
|||
| No. of patients |
90 |
89 |
- |
| Male (proportion in %) |
51 (57) |
60 (67) |
0.16 |
| Female (proportion in %) |
39 (43) |
29 (33) |
|
| Age (years): median |
10.4 |
7.2 |
0.52 |
| IQRΔ |
5.2 to 14.7 |
3.7 to 16.1 |
|
| Range |
0.2 to 35.2 |
0.0 to 35.4 |
|
| CVAD utilization days |
|||
| Cumulative No. |
6,086 |
6,705 |
# |
| Port |
3,672 |
3,989 |
|
| Broviac |
2,414 |
2,716 |
|
| Malignancy No. (%) |
0.09 |
||
| ALL |
21 (23) |
26 (29) |
|
| AML |
3 (3) |
6 (7) |
|
| NHL and HD |
15 (17) |
7 (8) |
|
| Solid tumor |
30 (33) |
22 (25) |
|
| ZNS |
18 (20) |
27 (30) |
|
| MAS |
2 (2) |
0 (0) |
|
| MDS |
0 (0) |
1 (1) |
|
| LCH |
1 (1) |
0 (0) |
|
| Malignancy in relapse No. (%) |
16 (18) |
13 (15) |
0.69 |
| No of patients with |
0.41 |
||
| Port (proportion in %) |
68 (76) |
62 (70) |
|
| Broviac (proportion in %) |
22 (24) |
27 (30) |
|
| CVAD removal due to infection: No. (%) |
4 (4.4) |
3 (3.4)Ω |
1.00 |
|
Group 1 = heparin (2003–2005) vs. group 2 = TauroLock™ (2005–2007) MAS Hemophagocytic lymphohistiocytosis, MDS myelodysplastic syndrome, LCH Langerhans Cell Histiocytosis. * CoNS = Coagulase-negative staphylococci. Δ IQR = Interquartile range, 25–75. Percentile # Utilization days per individual patient were not available; thus, P-values could not be calculated. Ω None of these due to Gram positive infections caused by CoNS or MRSE | |||
Simon et al. BMC Infectious Diseases 2008 8:102 doi:10.1186/1471-2334-8-102 |
|||